Michigan, US-based biopharmaceutical firm ProNAi Therapeutics landed $60 million in its Series D funding round led by Vivo Capital to advance its cancer treatment drugs to the second phase of clinical trials.
RA Capital Management
Breaking News
Cambridge-based anti-obesity drug developer Zafgen Inc bagged another USD45 million in a Series E funding round today, bringing its total funding to date to USD114 million.
Subscribe to VCpost newsletter
Most Popular
- Where's My Child Tax Credit 2024: When to Receive My Money After April 15 Tax Filing Deadline?
- SSDI Payment April 2024: Who Will Receive Social Security Benefits Today?
- Indiana Children's Museum Reportedly Exposed Total Solar Eclipse Watchers to Measles
- How to Get IRS Unclaimed Tax Refunds: Here's What to Do If You Think You Have Pending Payments
- Philippines Wants US, Japan to Fund Freight Railway Project After It Drops Funding Talks With China
- Kroger and Albertsons to Sell off 166 Stores in Effort to Gain Approval for Their $25 Billion Merger
- Student Loan Forgiveness Processing for This Group of Borrowers Will Stop Next Week
- FTC Sues to Block $8.5 Billion Merger of Coach and Michael Kors Handbag Makers